XML 67 R49.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Commitments and Contingencies (Details) |  |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 04, 2017 USD ($) | Jun. 29, 2017 USD ($) | Jan. 09, 2017 USD ($) | May 02, 2016 USD ($) | Feb. 28, 2018 USD ($) | Mar. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) employee | Dec. 31, 2016 USD ($) | Apr. 30, 2012 USD ($)
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  | $ 4,545,000 | $ 1,496,000 |
Payments to HPI over three-year period |  |  |  | $ 750,000 |  |  |  |  |
Buy-out option payment to HPI |  |  |  | $ 1,000,000 |  |  |  |  |
Licensing agreement term |  |  |  | 3 years |  |  |  |  |
Employee agreement, termination benefits, number of employees | employee |  |  |  |  |  |  | 4 |  |
Termination benefits provided to key employees, aggregate amount |  |  |  |  |  |  | $ 1,000,000 |  |
Annamed Agreement |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
One-time license documentation fee |  | $ 40,000 |  |  |  |  |  |  |
License agreement, annual maintenance fee |  | 25,000 |  |  |  |  |  |  |
Commencement Of Phase II Study For a Licensed Product | IntertechBio Agreement |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments liabilities |  |  |  |  |  |  |  |  | $ 200,000
Receipt Of Market Approval For a Licensed Product | Annamed Agreement |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments liabilities |  | 225,000 |  |  |  |  |  |  |
Receipt Of Market Approval For a Licensed Product | Moleculin Agreement |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments liabilities |  |  |  |  |  |  | 600,000 |  |
Receipt Of Market Approval For a Licensed Product | IntertechBio Agreement |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments liabilities |  |  |  |  |  |  |  |  | 500,000
Commencement Of Phase III Study For a Licensed Product | Annamed Agreement |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments liabilities |  | 125,000 |  |  |  |  |  |  |
Commencement Of Phase III Study For a Licensed Product | Moleculin Agreement |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments liabilities |  |  |  |  |  |  | 150,000 |  |
Commencement Of Phase III Study For a Licensed Product | IntertechBio Agreement |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments liabilities |  |  |  |  |  |  |  |  | 250,000
Submission Of First NDA Within United States | Annamed Agreement |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments liabilities |  | $ 175,000 |  |  |  |  |  |  |
Submission Of First NDA Within United States | Moleculin Agreement |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments liabilities |  |  |  |  |  |  | 500,000 |  |
Filing Of a New Drug Application For a Licensed Product | IntertechBio Agreement |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments liabilities |  |  |  |  |  |  |  |  | 400,000
Houston Pharmaceuticals, Inc |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
License fees |  |  |  |  |  |  | 225,000 | 75,000 |
MD Anderson |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Payments for research and development agreement | $ 346,687 |  | $ 302,500 |  |  |  |  |  |
Payments for research and development agreement, next twelve months | $ 110,000 |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  | 291,687 | 33,000 |
MD Anderson | Annamed Agreement |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
License fees |  |  |  |  |  |  | 52,500 | 0 |
MD Anderson | Moleculin Agreement |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
License fees |  |  |  |  |  |  | 85,000 | 77,500 |
MD Anderson | IntertechBio Agreement |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
License fees |  |  |  |  |  |  | $ 95,000 | $ 75,000 |
MD Anderson | IntertechBio Agreement | Servicing Fee payable |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Annual maintenance fee, first anniversary |  |  |  |  |  |  |  |  | 10,000
Annual maintenance fee, second anniversary |  |  |  |  |  |  |  |  | 20,000
Annual maintenance fee, third anniversary |  |  |  |  |  |  |  |  | 40,000
Annual maintenance fee, fourth anniversary |  |  |  |  |  |  |  |  | 60,000
Annual maintenance fee, fifth anniversary |  |  |  |  |  |  |  |  | 80,000
Annual maintenance fee, sixth anniversary |  |  |  |  |  |  |  |  | 100,000
Annual royalty payment, third anniversary following first sale |  |  |  |  |  |  |  |  | 600,000
MD Anderson | IntertechBio Agreement | Minimum Annual Royalty |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Annual royalty payment, first anniversary following first sale |  |  |  |  |  |  |  |  | 200,000
Annual royalty payment, second anniversary following first sale |  |  |  |  |  |  |  |  | $ 400,000
MD Anderson | Subsequent Event |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Payments for research and development agreement |  |  |  |  |  | $ 236,687 |  |  |
License agreement, annual maintenance fee |  |  |  |  | $ 10,000 |  |  |  |
License agreement, maintenance fee annual increase |  |  |  |  | 5,000 |  |  |  |
Minimum royalty payment per year |  |  |  |  | 200,000 |  |  |  |
License agreement, maintenance fee - maximum payable per year |  |  |  |  | $ 50,000 |  |  |  |
MD Anderson | Subsequent Event | Minimum |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Royalty on net revenues (as a percent) |  |  |  |  | 3.00% |  |  |  |
MD Anderson | Subsequent Event | Maximum |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Royalty on net revenues (as a percent) |  |  |  |  | 5.00% |  |  |  |
MD Anderson | Subsequent Event | Commencement Of Phase II Study For a Licensed Product |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Additional payments due |  |  |  |  | $ 150,000 |  |  |  |
MD Anderson | Subsequent Event | Submission Of A New Drug Application |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Additional payments due |  |  |  |  | 500,000 |  |  |  |
MD Anderson | Subsequent Event | Receipt Of Market Approval For a Licensed Product |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Additional payments due |  |  |  |  | $ 600,000 |  |  |  |

X
- Definition Amount of contractual obligation due in the next fiscal year following the latest fiscal year after product approval. + References No definition available. + Details
Name: | mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval
Namespace Prefix: | mbrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contractual obligation due in the second fiscal year following the latest fiscal year after product approval. + References No definition available. + Details
Name: | mbrx_ContractualObligationDueInSecondYearAfterProductApproval
Namespace Prefix: | mbrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contractual obligation due in the third fiscal year following the latest fiscal year after product approval. + References No definition available. + Details
Name: | mbrx_ContractualObligationDueInThirdYearAfterProductApproval
Namespace Prefix: | mbrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Employee Agreements, Special Termination Benefits, Number of Employees + References No definition available. + Details
Name: | mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees
Namespace Prefix: | mbrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Employee Agreements, Termination Benefits Provided To Key Employees, Aggregate Amount + References No definition available. + Details
Name: | mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount
Namespace Prefix: | mbrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License Agreement, Documentation Fee + References No definition available. + Details
Name: | mbrx_LicenseAgreementDocumentationFee
Namespace Prefix: | mbrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The annual maintenance fee under the licensing agreement. + References No definition available. + Details
Name: | mbrx_LicenseAgreementMaintenanceFee
Namespace Prefix: | mbrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The rate of increase annually on the annual maintenance fee under the licensing agreement. + References No definition available. + Details
Name: | mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease
Namespace Prefix: | mbrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the maximum payable amount of annual maintenance fee under the licensing agreement. + References No definition available. + Details
Name: | mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear
Namespace Prefix: | mbrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Licensing Agreement, Term + References No definition available. + Details
Name: | mbrx_LicensingAgreementTerm
Namespace Prefix: | mbrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Carrying amount of expense payable towards milestone payments under Patent and Technology License Agreement. + References No definition available. + Details
Name: | mbrx_MilestonePaymentsLiabilities
Namespace Prefix: | mbrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Payments For Research And Development Agreement + References No definition available. + Details
Name: | mbrx_PaymentsForResearchAndDevelopmentAgreement
Namespace Prefix: | mbrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payments For Research And Development Agreement, Next Twelve Months + References No definition available. + Details
Name: | mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths
Namespace Prefix: | mbrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payments For Royalties, Minimum Per Year + References No definition available. + Details
Name: | mbrx_PaymentsForRoyaltiesMinimumPerYear
Namespace Prefix: | mbrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research And Development Milestone Payments Due + References No definition available. + Details
Name: | mbrx_ResearchAndDevelopmentMilestonePaymentsDue
Namespace Prefix: | mbrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition It represents the royalty percentage on net revenue. + References No definition available. + Details
Name: | mbrx_RoyaltyOnNetRevenuesPercentage
Namespace Prefix: | mbrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of liabilities assumed at the acquisition date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contractual obligation due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_ContractualObligationDueAfterFifthYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contractual obligation due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_ContractualObligationDueInFifthYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contractual obligation due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_ContractualObligationDueInFourthYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contractual obligation due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_ContractualObligationDueInNextTwelveMonths
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_ContractualObligationDueInSecondYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contractual obligation due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_ContractualObligationDueInThirdYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | mbrx_AgreementAxis=mbrx_AnnamedAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_CommencementOfPhaseIiStudyForLicensedProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mbrx_AgreementAxis=mbrx_IntertechBioAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_ReceiptOfMarketApprovalForLicensedProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mbrx_AgreementAxis=mbrx_MoleculinAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_FilingOfNewDrugApplicationForLicensedProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=mbrx_HoustonPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=mbrx_MdAndersonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=mbrx_ServicingFeePayableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=mbrx_MinimumAnnualRoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_SubmissionOfANewDrugApplicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |